top of page
Search

Transitioning from Prolia to Estrogen

Updated: Dec 9, 2025


Can You Transition from Prolia to Estrogen?


The Evidence and the Safe Pathway

One of the most common questions in osteoporosis care is whether a woman can safely move off Prolia (denosumab) and transition onto estrogen therapy alone. The short answer is no. You cannot transition directly from Prolia to estrogen. Estrogen is not strong enough to cover the rebound effect that occurs when Prolia is stopped, and the risk of multiple vertebral fractures becomes dangerously high.

However, there are safe strategies if Prolia must be stopped. These involve oral or intravenous bisphosphonates, careful monitoring and long-term consolidation therapy.

This article explains the evidence, the risks and what current guidelines recommend.

Why You Cannot Transition from Prolia to Estrogen Alone

Prolia works by switching off RANKL, which stops osteoclasts from breaking down bone. Because of this, bone turnover is profoundly suppressed. The moment Prolia is stopped, bone turnover rebounds aggressively, often above pre-treatment baseline.


What the evidence shows

When Prolia is stopped:

  • Bone resorption rises rapidly within months.

  • Bone mineral density drops sharply within 6 to 12 months.

  • Vertebral fractures can occur suddenly, often multiple, and sometimes within 7 to 10 months of the last dose.

  • This phenomenon is known as the rebound effect.


Estrogen is not strong enough to counter this rapid rebound.It protects bone gradually and is appropriate for osteopenia or early menopause, not for stopping denosumab.

Therefore, transitioning directly from Prolia to estrogen is unsafe and not supported by any major osteoporosis guideline.


If Prolia Must Be Stopped, What Is the Safe Approach?

In rare cases where Prolia must be discontinued due to intolerance or unavoidable medical reasons, the evidence-based approach is to immediately place the patient on a potent antiresorptive, usually a bisphosphonate.

1. Oral Bisphosphonates

  • Alendronate weekly or

  • Risedronate weekly or monthly

These bind to bone and slow down osteoclast activity. They are used not to build bone, but to prevent the dangerous rebound effect after stopping Prolia.

2. Intravenous Zoledronic Acid (if needed)

If oral bisphosphonates are not tolerated or not effective, an infusion of zoledronic acid is recommended about 6 months after the last Prolia injection.

Zoledronic acid is stronger and can better blunt the rebound effect.


How Long Must a Woman Stay on Bisphosphonates After Stopping Prolia?

The true answer: several years.

Current expert consensus is:

  • Oral bisphosphonates for at least 1 to 2 years, often longer

  • With ongoing bone density monitoring

  • With additional IV zoledronic acid if the rebound effect persists

Many specialists aim for a stable bone density for about 3 to 5 years before considering a drug holiday.

Even then, holidays are only considered in women who:

  • have no fractures

  • have higher T-scores

  • have stable DEXA scans

  • are not at high risk

And importantly, drug holidays are for bisphosphonates, not Prolia. You cannot have a drug holiday from Prolia.Stopping it without consolidation therapy is dangerous.


Why Estrogen Is Not a Replacement for Prolia

Estrogen:

  • reduces bone resorption

  • is excellent for early postmenopausal bone loss

  • improves symptoms such as hot flashes and poor sleep

  • is helpful for osteopenia

But estrogen:

  • does not block the rebound surge of bone resorption

  • does not act quickly or strongly enough

  • cannot stabilise bone after Prolia withdrawal

  • cannot prevent rebound vertebral fractures

Estrogen can support long-term bone health after the skeleton has been stabilised with bisphosphonates, but it cannot replace the essential consolidation phase.


Can Estrogen Be Added Later for Symptoms?

Yes.

Once bone density is stabilised on a bisphosphonate for a few years, estrogen may be added:

  • for menopausal symptom relief

  • for additional bone protection

  • for metabolic and cardiovascular benefits in appropriate women

But not as the primary therapy after Prolia.


So What Does the Evidence-Based Sequence Look Like?

If Prolia is stopped:

Prolia → Oral Bisphosphonate (or IV Zoledronic Acid) → Long-term stability → Possible adjunct estrogen

There is no evidence-supported sequence that looks like:

Prolia → Estrogen alone

That pathway is unsafe and carries an increased risk of vertebral fracture.


Summary

  • You cannot transition from Prolia to estrogen alone.

  • Prolia discontinuation causes rapid bone loss and vertebral fractures unless covered by a bisphosphonate.

  • Oral bisphosphonates or IV zoledronic acid are used as consolidation therapy for several years.

  • Many specialists aim for about 3 to 5 years of stability before considering a bisphosphonate drug holiday.

  • Estrogen can be used later for symptoms or additional support, but it cannot replace the essential post-Prolia antiresorptive phase.


    In rare cases where Prolia must be stopped, specialist-led management is essential.


By Dr Purity Carr

GP & Menopause Doctor

Harvey, WA, #drpuritycarr

 
 
 

Comments

Welcome to Purity Health Women’s Menopause and Wellbeing Centre™

​

At Purity Health, we believe in living life to the fullest. Dr Purity Menopause Clinic, in association with Samy Medical Group, is dedicated to providing safe, evidence based information and care in perimenopause, menopause, histamine related conditions, and metabolic health.

​

We recognise that there are many myths and misunderstandings surrounding menopause and Hormone Replacement Therapy, HRT. One commonly repeated belief is that oestrogen causes breast cancer. This is an oversimplification and does not reflect the full body of evidence.

​

Here is the truth.

At Dr Purity Carr Menopause Clinic, we are committed to providing accurate information and personalised care.

Follow us on #drpuritycarr

Extensive evidence shows that for women within 10 years of menopause or under the age of 60, the benefits of HRT generally outweigh the risks.

​

For women who start HRT during perimenopause or within 10 years of menopause, there is often no need to stop purely based on age. Ongoing use should be individualised and guided by clinical review.

Even for women who are further beyond menopause or over 60, starting HRT may still be considered under the guidance of a knowledgeable practitioner, with careful assessment of risks and benefits.

​

A Broader Approach to Women’s Health

Dr Purity is a General Practitioner with a special interest in menopause care, taking a holistic, systems based approach to women’s health.

​

In addition to menopause, her work now includes:

Hormone health, including perimenopause and menopause
Histamine related conditions, including suspected mast cell activation patterns
Metabolic health, including weight management, insulin resistance, and inflammation
The interaction between hormones, the immune system, and the nervous system

Many women experience symptoms that do not sit neatly within one system. Hormones do not operate in isolation. There is often an overlap between hormonal changes, histamine activity, and metabolic dysfunction. This integrated approach allows for a deeper understanding of symptoms such as fatigue, anxiety, poor sleep, weight gain, brain fog, and chronic inflammation.

 

Dr Purity’s Focus on Care

Dr Purity focuses specifically on menopause, histamine balance, and metabolic health. She works to identify underlying drivers of symptoms and supports women through evidence based, personalised care.

Please note that Dr Purity does not replace your general practitioner. The experienced doctors at Samy Medical, part of the same medical system as Purity Health, are available to manage your broader healthcare needs.

bottom of page